KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Shares Outstanding (Diluted Average): 2010-2025

Historic Shares Outstanding (Diluted Average) for Emergent BioSolutions (EBS) over the last 14 years, with Sep 2025 value amounting to $56.7 million.

  • Emergent BioSolutions' Shares Outstanding (Diluted Average) rose 1.98% to $56.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.7 million, marking a year-over-year increase of 1.98%. This contributed to the annual value of $53.0 million for FY2024, which is 3.52% up from last year.
  • Per Emergent BioSolutions' latest filing, its Shares Outstanding (Diluted Average) stood at $56.7 million for Q3 2025, which was down 0.00% from $56.7 million recorded in Q2 2025.
  • Emergent BioSolutions' Shares Outstanding (Diluted Average)'s 5-year high stood at $57.3 million during Q1 2025, with a 5-year trough of $50.1 million in Q4 2022.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $52.6 million (2024), whereas its average is $53.5 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Shares Outstanding (Diluted Average) dropped by 7.55% in 2022, and later rose by 9.77% in 2025.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Shares Outstanding (Diluted Average) stood at $54.1 million in 2021, then dropped by 7.39% to $50.1 million in 2022, then climbed by 2.20% to $51.2 million in 2023, then grew by 3.52% to $53.0 million in 2024, then rose by 1.98% to $56.7 million in 2025.
  • Its last three reported values are $56.7 million in Q3 2025, $56.7 million for Q2 2025, and $57.3 million during Q1 2025.